Page 3 - Andrea Carfi News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
sciencemag.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sciencemag.org Daily Mail and Mail on Sunday newspapers.
Two COVID-19 vaccines show safety, strong immunity in infant model
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
A Universal Vaccine May Soon Protect Against All Coronaviruses, Including the Common Cold
On 05/12/21 at 5:00 AM EDT
Jason S. McLellan, associate professor of molecular biosciences, left, and graduate student Daniel Wrapp, right, work in the McLellan Lab at The University of Texas at Austin in 2020.
Vivian Abagiu/College of Natural Sciences at UT Austin
It took Barney Graham, Jason McLellan and their collaborators just a weekend in January 2020 to design a novel vaccine they believed would be capable of protecting people against COVID-19. Their design formed the basis for the vaccines that Moderna, Pfizer and others would eventually use to inoculate millions of Americans a little more than a year later, a pace of development unprecedented in the annals of modern medicine.
As hopes rise for pandemicâs close, some are preparing for never-ending COVID
Scores of companies, many in Massachusetts, gear up to fight the virus âin perpetuityâ
By Robert Weisman and Jonathan Saltzman Globe Staff,Updated April 24, 2021, 1 hour ago
Email to a Friend
Vaccinations are continuing in Boston at the Harvard Street Neighborhood Health Center clinic at the Prince Hall Grand Lodge. People may need booster shots in the future.Craig F. Walker/Globe Staff
A pandemic-weary public is dreaming of Memorial Day barbecues, summer nights at Fenway Park, and putting the long-running curse of COVID-19 behind us.
But in the medical and biopharma worlds, many are eyeing a more daunting prospect: coronavirus as a never-ending threat.